Bausch + Lomb (BLCO)

• Market cap: $4.97B
• 1 day: -2.69%
• 5 days: -11.42%
• 1 month: -11.03%
• 3 months: -21.61%
• 6 months: -26.28%
• Year to date: -21.61%
• 1 year: -17.29%
• 5 years: -29.45%
• 10 years: -29.45%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,500

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

21% more call options, than puts

Call options by funds: $5.9M | Put options by funds: $4.89M

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

2% more funds holding

Funds holding: 110 [Q3] → 112 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

1.02% less ownership

Funds ownership: 10.74% [Q3] → 9.71% (-1.02%) [Q4]

15% less capital invested

Capital invested by funds: $729M [Q3] → $618M (-$111M) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 6% upside
• Avg. target: $17.60 25% upside
• High target: $20 42% upside

5 analyst ratings

• positive: 2 40%
• neutral: 2 40%
• negative: 1 20%

Wells Fargo Larry Biegelsen 36% 1-year accuracy 17 / 47 met price target	6% upside $15	Equal-Weight Downgraded	28 Mar 2025
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 63 / 167 met price target	42% upside $20	Buy Maintained	21 Feb 2025
RBC Capital Douglas Miehm 46% 1-year accuracy 11 / 24 met price target	28% upside $18	Outperform Maintained	20 Feb 2025
B of A Securities Craig Bijou 50% 1-year accuracy 5 / 10 met price target	20% upside $17	Underperform Maintained	20 Feb 2025
Stifel Thomas Stephan 33% 1-year accuracy 5 / 15 met price target	28% upside $18	Hold Maintained	29 Jan 2025